Phillip Md Et Al Frost Purchases 125,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 125,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were purchased at an average cost of $1.59 per share, for a total transaction of $198,750.00. Following the transaction, the chief executive officer now owns 212,536,477 shares of the company’s stock, valued at $337,932,998.43. This trade represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 11th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost bought 199,072 shares of OPKO Health stock. The stock was acquired at an average cost of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was bought at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.59 on Friday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a 50 day simple moving average of $1.53 and a 200-day simple moving average of $1.47. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -8.37 and a beta of 1.62. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.76.

Wall Street Analyst Weigh In

Several research analysts have weighed in on OPK shares. Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Thursday, September 26th. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP increased its holdings in shares of OPKO Health by 9.6% in the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after acquiring an additional 876,272 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of OPKO Health during the 2nd quarter worth approximately $592,000. Y.D. More Investments Ltd acquired a new stake in shares of OPKO Health in the 2nd quarter worth approximately $1,840,000. Finally, Comerica Bank increased its stake in OPKO Health by 125.0% in the 1st quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.